Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Merck, Orphazyme, Sanofi.
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Co-Diagnostics, Hecin, Holista Colltech.
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Boston Scientific, Edevice, Genesis Medtech Group, Horcon, Inivata, Neogenomics, Pattern Computer, Predictmedix, Rakuten Medical, Shimadzu.
About a year-and-a-half after the sequencing of the SARS-CoV-2 virus and the onslaught of COVID-19 therapeutic and vaccine development that followed, the biopharma industry boldly tackles a slew of ongoing issues from vaccine hesitancy and supply inequities to the ramifications of a potential intellectual property waiver and the pressing need to prepare global systems for the next pandemic.
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Aim, Altan, Antengene, Astrazeneca, Athira, Ethypharm.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Biogen, Curevac, Harbour, Kancera, Pfizer, Qpex, Satsuma, Targovax, Tarsus, Viking.
Diagnostics powerhouse Danaher Corp. has agreed to buy Aldevron LLC, a privately held biotech company that supplies a key ingredient for COVID-19 vaccines, from EQT VIII Fund for $9.6 billion in cash. Based in Fargo, N.D., with additional operations in Madison, Wis., Aldevron makes high-quality plasmid DNA, mRNA and recombinant proteins used in vaccines, gene and cell therapy, gene editing and diagnostic applications.